Pneumologie : asthme, BPCO et syndrome d'apnées du sommeil

Abstract

Among the novelties described in the management of pulmonary disorders during the year 2017, we chose to describe three. First, the indication for inhaled glucocorticosteroids (ICS) in COPD has been revisited, because of their relationship with an increased occurence of pneumonia : ICS are now recommended only in severe COPD (GOLD D) with frequent exacerbations as second line treatment. Secondly, azithromycine has shown very promising results in poorly controlled severe asthma, with a significant impact on symptoms and exacerbations. Finally, despite the association between sleep apnea syndrome and cardiovascular morbidity, the prescription of CPAP in asymptomatic individuals as primary or secondary prevention is not supported by the recent literature